In prostate cancer explants, HSP90 inhibitor AUY922 also reduced FN secretion (Armstrong et al. 2018), while FN expression was stimulated by HSP90 inhibitor geldanamycin in an HSF1-dependent manner (Dhanani et al. 2017). Here, HSP90AB1 is linked to prostate carcinoma.